The ESMO Magnitude of Clinical Benefit Scale uses a rational, structured and consistent approach to derive a relative ranking of the magnitude of clinically meaningful benefit that can be expected from a new anti-cancer treatment
There are four evalutation forms, which can be downloaded below:
Evaluation form 1
For new approaches to adjuvant therapy or new potentially curative therapies
Hyper mature data from studies that were un-blinded after compelling early results with subsequent access to the superior arm are contaminated, subsequently late intention to treat (ITT) follow-up data are not evaluable
Evaluation form 2a
For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
- IF median OS with the standard treatment is < 1 year
- IF median OS with the standard treatment > 1 year
Evaluation form 2b
For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
- IF median PFS with standard treatment < 6 months
- IF median PFS with standard treatment > 6 months
Evaluation form 2c
For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent studies